

DAFTAR PUSTAKA

1. Fauci et al. Severe Sepsis and Septic Shock. Harison's: Principles of Internal Medicine 17th Ed. USA: The McGraw Hill Companies;2008.E-book version.
2. Guntur A. SIRS & SEPSIS : Imunologi, Diagnosis, Penatalaksanaan. Surakarta: Sebelas Maret Press;2006. p. 1-13.
3. Trevino S, Ross D. Bacteremia and Sepsis. In Mahon CR, Lehman DC, Manuselis G. Textbook of Diagnostic Microbiology. 3rd Edition. China: Saunders el sevier :2007.p.996-1001.
4. Bone et al. Definition for sepsis and organ failure and guidelines for the use of innovative therapy for sepsis. Chest [Internet]. 1992. [cited 2012 December 24];101(6):1644-55, Available from : <http://www.ncbi.nlm.nih.gov/pubmed/1303622>
5. Lever A. Mackenzie I.Sepsis: definition, epidemiology, and diagnosis. BMJ [Internet].2007.[cited 2012 8 October];335(7625): 879–83. Available from : www.bmj.com
6. Moore, Laura J. MD, Bruce A. PhD; Turner, Krista L. MD, et al. The Epidemiology of Sepsis in General Surgery Patients. Journal of Trauma-Injury Infection & Critical Care:March 2011;70: 672-80.
7. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med [Internet]. 2003 [cited 2012 October 8] ;348:1546-54. Available from : www.nejm.org
8. Nachtigall I, Tamarkin A, Tafelski S, et al. Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. Crit Care Med 2009;37:159-166.
9. Perez F, Salman S. Pendem S. et al. Sepsis during pregnancy. Critical Care Medicine.2005; 33(10):286-90
10. Sharma S, Kumar A. Antimicrobial management of sepsis and septic shock. Clin Chest Med. 2008;29(4):677-87.

11. Schmidt GA, Mandel J. Management of Severe Sepsis and septic shock in adults [Internet] 2009 [cited 2012 December 30]. Available from: http://www.utdol.com/home/content/topic.do?topicKey=cc_medi/16828.
12. Toltzis P, Dul M, O’Riordan MA, Melnick D, Lo M, Blumer J. Meropenem use and colonization by antibiotic-resistant Gramnegative bacilli in a pediatric intensive care unit. *Pediatr Crit Care Med*. 2009;10(1):49-54.
13. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. *Crit Care Med*. 2004;32(11 Suppl):S495512.
14. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. *Chest* 2004; 125:1791–99.
15. Textoris J, Wiramus S, Martin C, Leone M. Overview of antimicrobial therapy in intensive care units. *Expert Rev Anti Infect Ther*. 2011; 9:97–109.
16. Jonathan Cohen. The immunopathogenesis of sepsis. *Nature* [Internet]. 2002 [cited 2012 October 8]; 420:885-91. Available from: www.nature.com/nature.
17. Munford RS. Sepsis, Severe Sepsis, and Sepsic Shock. In : Mandel GL, Bennet JE, Dolin R. Mandell, Douglas, and Barnett’s : Principles and Practice of Infectious Disease. 6th edition. Vol. 1. USA: Elsevier Churchill Livingstone;2005.p.906,913-5
18. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC case mix programme database. *Crit Care* [Internet]. 2006. [cited 2012 October 8];. Available from : www.ncbi.nlm.nih.gov/pubmed/16542492
19. Silva E. et al. Brazilian Sepsis Epidemiological Study (BASES study). *Crit Care* [Internet]2004[cited 2012 December 24] ;8:R251-R260. Available from : <http://ccforum.com/content/8/4R251>

20. Kristine MJ, Sarah BL, Annacrine LP, Jesper EO and Thomas B. Common TNF α , IL-1 β , PAI-1, uPA, CD14 dan TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. *BMC Infect Dis* [Internet]. 2007 [cited 2012 October 24]; 7:108. Available from : <http://www.biomedcentral.com/1471-2334/7/108>
21. Elena GR, Alejo C, Gema R, and Mario D. Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. *J Exp Med* March [Internet]. 2006 [cited 2012 December 24]; 203(2):563-571. Available from : www.ncbi.nlm.nih.gov
22. Arul MC, Markus HL, Chandan KS, Terrence RB, Sunita SS, Vidya JS et al. 2001. Molecular Signatures of Sepsis Multiorgan Gene Expression Profiles of Systemic Inflammation. *Am J Pathol* October 159(4): 1199-1209
23. Landry DW, Oliver JA : The Pathogenesis of Vasodilatory Shock. *N Engl J Med* [Internet]. 2001 [cited 2012 October 2012] ;345:588-595. Available from : www.nejm.org
24. Marshall JC . Inflammation coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. *Crit Care Med*. 2001;29:99-106
25. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* [Internet] 2003 [cited 2012 October 7] ;326:41-4. Available from : <http://www.bmj.com/content/335/7625/879>
26. Jawetz E, Melnick JL, Adelberg EA, Brooks GF, Butel JS, Ornston LN. Kemoterapi antimikroba. Di dalam : Setiawan I, editor. *Mikrobiologi kedokteran*. Jakarta: EGC, 1996: 153-64.
27. Arvin AM. Penggunaan klinis laboratorium mikrobiologi. Di dalam : Wahab AS, editor. *Ilmu kesehatan anak nelson*. Jakarta: EGC, 1999:856-61.
28. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. *Crit Care Med* 2003; 31:462–467.

29. Depuydt P, Blot S. Antibiotic therapy for ventilator-associated pneumonia: de-escalation in the real world. *Crit Care Med* 2007; 35:632–633.
30. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. *Crit Care Med* 2007; 35:379–385.
31. Textoris J, Wirasmus S, et al. Antibiotic therapy in patients with septic shock. *Crit Care Med* 2011;28:318-324
32. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005; 171:388–416.
33. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008; 36:296–327.
34. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a five fold reduction of survival in human septic shock. *Chest* 2009; 136:1237–1248.
35. Chambers HF. Penicillins, cephalosporins, and other β -lactam antibiotics. In, Brunton LL, Lazo JS, and Parker KL (eds). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. New York: McGraw-Hill, 2006. p. 1127-54
36. Petri WA. Penicilins, cephalosporin, and other beta-lactam antibiotics. In : Brunton LL, Lazo JS, Parker KL. *Goodman and Gillman's: The Pharmacological Basic of Therapeutics*. 11th ed. New York: McGraw-Hill;2006.p.1127-54
37. Istiantoro YH, Gan VHS. Penisilin, sefalosporin dan antibiotika beta-laktam lainnya . Dalam : Gunawan SG, Setiabudi R, Nafrialdi, Elysbeth. *Farmakologi dan Terapi*. Edisi 5. Jakarta: Departemen Farmakologi dan Terapuetik FK UI ; 2007. Hal. 678-83.
38. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. *Drug Saf.* 2007; 30: 657-68

39. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. *Clin Infect Dis* [Internet]. 2005 [cited 2013 January 13]; 41 (Suppl 2): S144-57. Available from : <http://cid.oxfordjournals.org/>
40. Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. *Curr Med Res Opin* 2007; 23: 1403-13. Erratum in: *Curr Med Res Opin* 2007; 23: 2303
41. Moseley RH. Antibacterial and Antifungal Agents. In, Kaplowitz N, DeLeve LD, eds. *Drug-induced liver disease*. 2nd Edition. New York: Informa Healthcare USA, Inc, 2007. p. 527-46
42. Stitzel, R. E and C. R. Craig, *Moddern Pharmacology*, 2005
43. Augustin P, Kermarrec N. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. 2010. *Crit Care* 2010;14:R20.
44. Anton Y. Peleg, M.B., B.S., M.P.H., and David C. Hooper, M.D., *Current Concepts, Hospital-Acquired Infections Due to Gram-Negative Bacteria*, *n engl j med* [Internet]. 2010. [cited 2013 January 13] ;362;19. Available from : www.nejm.org
45. Cesar A. Arias, M.D., Ph.D., and Barbara E. Murray, M.D. Antibiotic-Resistant Bugs in the 21st Century —A Clinical Super-Challenge, *n engl j med* [Internet] 2009. [cited 2013 January 13];360;5. Available from : www.nejm.org
46. Departemen Kesehatan RI, *Standar Pelayanan Intensive Care Unit*, Jakarta, 2003
47. *Guidelines for ICU admission, discharge and triage*, American College of Critical Care Medicine of the Society of Critical Care Medicine, 1999

LAMPIRAN 3

Bakteri

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	S. epidermidis	11	100.0	100.0	100.0

Amikacin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	7	63.6	63.6	63.6
	Resisten	4	36.4	36.4	100.0
	Total	11	100.0	100.0	

Oxaciclin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	2	18.2	18.2	18.2
	Resisten	9	81.8	81.8	100.0
	Total	11	100.0	100.0	

Vancomicin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	11	100.0	100.0	100.0

Bakteri

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	P. aeruginosa	18	100.0	100.0	100.0

Cefepim

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	8	44.4	44.4	44.4
	Intermediet	2	11.1	11.1	55.6
	Resisten	8	44.4	44.4	100.0
	Total	18	100.0	100.0	

\

Ceftazidim

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	5	27.8	27.8	27.8
	Resisten	13	72.2	72.2	100.0
	Total	18	100.0	100.0	

Amikacin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	9	56.3	56.3	56.3
	Intermediet	2	12.5	12.5	68.8
	Resisten	5	31.3	31.3	100.0
	Total	16	100.0	100.0	

Meropenem

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	8	50.0	50.0	50.0
	Resisten	8	50.0	50.0	100.0
	Total	16	100.0	100.0	

Sulbactam-Cefoperazon

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Sensitif	10	90.9	90.9	90.9
	Resisten	1	9.1	9.1	100.0
	Total	11	100.0	100.0	

LAMPIRAN 4

BIODADATA MAHASISWA

Identitas

Nama : Indah Rahmawati
NIM : G2A009008
Tempat/tanggal lahir : Bima, 2 Juli 1991
Jenis Kelamin : Perempuan
Alamat : Jalan Gisik Sari IV No. 1078 Blok E-F Semarang
Nomor HP : 082327069911
Email : saya_indah19@yahoo.co.id

Riwayat Pendidikan Formal

- | | | |
|--------|-------------------|--------------------|
| 1. SD | : SDN No. 4 Tente | Lulus Tahun : 2003 |
| 2. SMP | : SMPN 1 Bima | Lulus Tahun : 2006 |
| 3. SMA | : SMAN 1 Bima | Lulus Tahun : 2009 |

Keanggotaan Organisasi

1. ROHIS KU Undip Tahun 2011 s/d 2012